Patent ID: 8901279

Claim:
A humanized antibody, comprising a VH binding domain having an amino acid sequence selected from the group consisting of the amino acid sequence of residues 1 to 120 of SEQ ID NO: 50, the amino acid sequence of residues 1 to 120 of SEQ ID NO: 38, an amino acid sequence having at least 95% identity with the amino acid sequence of residues 1 to 120 of SEQ ID NO: 50 provided that the residue at position 72 is Arg or Lys and that the VH CDR1 has the amino acid sequence of SEQ ID NO: 96, the VH CDR2 has the amino acid sequence of SEQ ID NO: 98, and the VH CDR3 has the amino acid sequence of SEQ ID NO: 100, and an amino acid sequence having at least 95% identity with the amino acid sequence of residues 1 to 120 of SEQ ID NO: 38 provided that the residue at position 72 is Arg or Lys and that the VH CDR1 has the amino acid sequence of SEQ ID NO: 96, the VH CDR2 has the amino acid sequence of SEQ ID NO: 98, and the VH CDR3 has the amino acid sequence of SEQ ID NO: 100, and a VL binding domain having an amino acid sequence selected from the group consisting of the amino acid sequence of residues 1 to 107 of SEQ ID NO: 7, the amino acid sequence of residues 1 to 107 of SEQ ID NO: 8, an amino acid sequence having at least 95% identity with the amino acid sequence of residues 1 to 107 of SEQ ID NO: 7 provided that the VL CDR1 has the amino acid sequence of SEQ ID NO: 188, the VL CDR2 has the amino acid sequence of SEQ ID NO: 190, and the VL CDR3 has the amino acid sequence of SEQ ID NO: 192, and an amino acid sequence having at least 95% identity with the amino acid sequence of residues 1 to 107 of SEQ ID NO: 8 provided that the VL CDR1 has the amino acid sequence of SEQ ID NO: 188, the VL CDR2 has the amino acid sequence of SEQ ID NO: 190, and the VL CDR3 has the amino acid sequence of SEQ ID NO: 192.